149 related articles for article (PubMed ID: 20492512)
21. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.
Forestier N; Reesink HW; Weegink CJ; McNair L; Kieffer TL; Chu HM; Purdy S; Jansen PL; Zeuzem S
Hepatology; 2007 Sep; 46(3):640-8. PubMed ID: 17879366
[TBL] [Abstract][Full Text] [Related]
22. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
Morishima C; Morgan TR; Everhart JE; Wright EC; Shiffman ML; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Gretch DR;
Hepatology; 2006 Aug; 44(2):360-7. PubMed ID: 16871570
[TBL] [Abstract][Full Text] [Related]
23. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy).
Bahra M; Neumann UP; Jacob D; Langrehr JM; Berg T; Neuhaus R; Neuhaus P
Transplantation; 2007 Feb; 83(3):351-3. PubMed ID: 17297412
[TBL] [Abstract][Full Text] [Related]
24. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.
Akhan SC; Kalender B; Ruzgar M
Infection; 2008 Aug; 36(4):341-4. PubMed ID: 18629437
[TBL] [Abstract][Full Text] [Related]
25. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
26. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
[TBL] [Abstract][Full Text] [Related]
27. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
28. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
Fried MW; Jensen DM; Rodriguez-Torres M; Nyberg LM; Di Bisceglie AM; Morgan TR; Pockros PJ; Lin A; Cupelli L; Duff F; Wang K; Nelson DR
Hepatology; 2008 Oct; 48(4):1033-43. PubMed ID: 18697207
[TBL] [Abstract][Full Text] [Related]
29. Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C.
McHutchison JG; Patel K; Schiff ER; Gitlin N; Mur RE; Everson GT; Carithers RL; Davis GL; Marcellin P; Shiffman ML; Harvey J; Albrecht JK;
Aliment Pharmacol Ther; 2008 Mar; 27(5):422-32. PubMed ID: 18081733
[TBL] [Abstract][Full Text] [Related]
30. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
[TBL] [Abstract][Full Text] [Related]
31. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
[TBL] [Abstract][Full Text] [Related]
32. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
Bader el-Din NG; Abd el-Meguid M; Tabll AA; Anany MA; Esmat G; Zayed N; Helmy A; el-Zayady AR; Barakat A; el-Awady MK
J Gastroenterol Hepatol; 2011 Jan; 26(1):55-62. PubMed ID: 21175794
[TBL] [Abstract][Full Text] [Related]
33. Chronic hepatitis C treatment in näive patients.
Daruich J
Ann Hepatol; 2010; 9 Suppl():65-71. PubMed ID: 20713999
[TBL] [Abstract][Full Text] [Related]
34. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
35. Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response.
Chu CY; Cheng CH; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
J Formos Med Assoc; 2019 Jul; 118(7):1129-1137. PubMed ID: 30472042
[TBL] [Abstract][Full Text] [Related]
36. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.
Martinez SM; Fernández-Varo G; González P; Sampson E; Bruguera M; Navasa M; Jiménez W; Sánchez-Tapias JM; Forns X
Aliment Pharmacol Ther; 2011 Jan; 33(1):138-48. PubMed ID: 21083589
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of the Peginterferon treatment in chronic hepatitis HDV and compensate liver cirrhosis.
Tugui L; Dumitru M; Iacob S; Gheorghe L; Preda C; Dinu I; Becheanu G; Dumbrava M; Nicolae I; Andrei A; Lupu A; Diculescu M
Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):368-75. PubMed ID: 25076702
[TBL] [Abstract][Full Text] [Related]
38. Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C.
Lorenzo-Zúñiga V; Bartolí R; Masnou H; Montoliu S; Morillas RM; Planas R
Dig Dis Sci; 2007 Nov; 52(11):3245-50. PubMed ID: 17410466
[TBL] [Abstract][Full Text] [Related]
39. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
Poynard T; Bruix J; Schiff ER; Diago M; Berg T; Moreno-Otero R; Lyra AC; Carrilho F; Griffel LH; Boparai N; Jiang R; Burroughs M; Brass CA; Albrecht JK
J Hepatol; 2013 Mar; 58(3):452-9. PubMed ID: 23159770
[TBL] [Abstract][Full Text] [Related]
40. Long term changes in liver histology following treatment of chronic hepatitis C virus.
Shiffman ML; Sterling RK; Contos M; Hubbard S; Long A; Luketic VA; Stravitz RT; Fuchs M; Sanyal AJ
Ann Hepatol; 2014; 13(4):340-9. PubMed ID: 24927604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
